Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
about
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.Src Dependent Pancreatic Acinar Injury Can Be Initiated Independent of an Increase in Cytosolic Calcium.The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III studyPhase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaHigh-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsOptimizing chemotherapy: concomitant medication listsGastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.Clinically significant drug interactions with antacids: an update.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Dasatinib for the treatment of chronic myeloid leukemia.Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Pepsi® or Coke®? Influence of acid on dasatinib absorption.Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner
P2860
Q33394487-5BAD7898-3041-410D-9F23-FEAAAD578810Q33397085-29F902BF-8D00-4B83-AD8E-BC37BD6DB4AEQ34786769-BA539022-ED84-4666-B5B4-F09C729F81E5Q34793419-0B47793F-6B4A-49FE-AA35-B88FF929D33DQ35318395-0F389A47-1EAD-46CF-B41E-3E10E2881542Q36933601-AC7788FC-4DA3-4CF6-B416-10AFB416F269Q36949546-47DE09E8-234F-457A-8C46-B0D5F1033E7FQ37209768-3E39A206-4D2F-40AB-8D33-075DF7BD03BCQ37304704-65E99E6D-AD7E-4313-BB91-C8E3E20E1642Q37624513-E63BBCFF-E231-4D48-9BAD-362157128AF1Q37937722-0799D7B2-89E3-4BAA-8E45-D6032F7E1BE7Q38022125-9F503777-CF8E-45CA-A3AC-FCA1418F86E1Q38044753-2CC44DB2-FF85-43A4-84CA-D071649FDF44Q38082728-843266D3-9F81-4DA2-96F8-88120B69B353Q38099040-23D43FBE-9AE1-49A6-8140-E4C7EFE739B3Q38198997-ACA3725B-499C-43B5-962D-21B54150F67FQ39350678-B801B00D-0774-4817-A145-DB4E71E4A863Q39411920-2269E99B-7EBA-4BA4-8E5F-6A24D16C983DQ39739850-41506783-8065-48FF-A2E3-0A0B7CBB34A3Q40260228-3338F2CD-6F73-4EDF-B235-74992783AB11Q41404243-7D66445D-95DE-46E6-9A10-70C1177744A4Q41763725-04BB8789-6597-43CF-B6F1-F761271695AEQ42770379-5276D8E8-5992-452D-99CF-51E0F78F8099Q43055360-7073CEC2-5E77-4F3C-B61F-369BE3BBDA3CQ43841175-FBA05766-D5F1-48C2-A3DC-4579702F9C35Q47969048-3FACB16C-944E-42C7-9084-2CA614986883Q48555829-F5F9546B-7724-4ABB-96A7-DDC191E76305Q50711101-DB63759E-C583-4297-B620-4948321AA62EQ51746806-5CEAE512-DF83-4255-A374-D916F8E13C56Q53357202-521B2AD3-A18C-47D0-847D-AF028D933AEFQ55060584-A5F17D51-72AC-46B9-A40D-42E0747FB213Q57498748-47D2E8A2-D735-4B5E-B1F7-867B709753C3
P2860
Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase I study of the effect of ...... dasatinib in healthy subjects.
@en
Phase I study of the effect of ...... dasatinib in healthy subjects.
@nl
type
label
Phase I study of the effect of ...... dasatinib in healthy subjects.
@en
Phase I study of the effect of ...... dasatinib in healthy subjects.
@nl
prefLabel
Phase I study of the effect of ...... dasatinib in healthy subjects.
@en
Phase I study of the effect of ...... dasatinib in healthy subjects.
@nl
P2093
P2860
P356
P1476
Phase I study of the effect of ...... dasatinib in healthy subjects.
@en
P2093
Anne Blackwood-Chirchir
Ashish Sanil
Feng R Luo
James Manning
Richard Bertz
Shruti Agrawal
Timothy Eley
P2860
P304
P356
10.1177/0091270009333854
P577
2009-04-24T00:00:00Z